SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Innovent Biologics, Inc. IVBXF OTC

Other OTC • Healthcare • Biotechnology • CN • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Innovent Biologics, Inc. (IVBXF) is a Biotechnology company in the Healthcare sector, currently trading at $10.55. It has a SharesGrow Score of 69/100, indicating a above average investment profile with 4 out of 7 criteria passed.

Financials: revenue is $12.7B, +41%/yr average growth. Net income is $793M, growing at +360.4%/yr. Net profit margin is 6.2% (thin). Gross margin is 86.5% (+6.9 pp trend).

Balance sheet: total debt is $2.8B against $19.4B equity (Debt-to-Equity (D/E) ratio 0.15, conservative). Current ratio is 2.62 (strong liquidity). Debt-to-assets is 7.5%. Total assets: $37.4B.

SharesGrow 7-Criteria breakdown: Value 75/100 (Pass), Growth 100/100 (Pass), Past 25/100 (Fail), Health 100/100 (Pass), Moat 84/100 (Pass), Future ?/100 (Fail), Income 45/100 (Partial).

IVBXF SharesGrow Score Overview

72/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 75/100

Valuation — P/E, PEG, Forward PEG

GROWTH 100/100

Financials — average growth

PAST 25/100

strong — trend

HEALTH 100/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 84/100

Gross margin is + market cap

FUTURE 0/100

Analyst outlook — as buy

INCOME 45/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — IVBXF

IVBXF trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

IVBXF: +41%/yr revenue is, +360.4%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

IVBXF: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet IVBXF: Debt-to-Equity (D/E) ratio 0.15 (conservative), Current ratio is 2.62 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

IVBXF: Gross margin is 86.5% (+6.9 pp trend), $18B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 84/100. ≥ 70 = Pass.

View details →

No analyst coverage available for this stock.

IVBXF: Net profit margin is 6.2%. thin (5-15%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range5.0001-15.12

Volume10

Avg Volume (30D)1.44K

Market Cap$18.15B

Beta (1Y)0.23

Share Statistics

EPS (TTM)0.47

Shares Outstanding$1.68B

IPO Date2019-09-04

Employees5,659

CEODe-Chao Yu

Financial Highlights & Ratios

Revenue (TTM)$12.7B

Gross Profit$10.99B

EBITDA$1.97B

Net Income$792.57M

Operating Income$1.97B

Total Cash$18.24B

Total Debt$2.82B

Net Debt$-14.54B

Total Assets$37.37B

Price / Earnings (P/E)22.4

Price / Sales (P/S)1.43

Analyst Forecast

Company Info

CountryCN

ExchangeOther OTC

CurrencyUSD

ISINKYG4818G1010

Price Chart

IVBXF

Innovent Biologics, Inc. ↗ · Other OTC

Healthcare • Biotechnology

5.00 52WK RANGE 15.12

People Also View

Crinetics Pharmaceuticals, Inc.

Telix Pharmaceuticals Limited

Genscript Biotech Corporation

Relay Therapeutics, Inc.

Arcus Biosciences, Inc.

Oxford Nanopore Technologies plc

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message